{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:12:32Z","timestamp":1794625952700,"version":"4.9.1"},"reference-count":83,"publisher":"European Respiratory Society (ERS)","issue":"173","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2024,5,9]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>\n                    Cystic fibrosis (CF) is a genetic disease caused by variants in the gene encoding for the CF transmembrane conductance regulator (CFTR) protein, a chloride and bicarbonate channel. CFTR dysfunction results in a multiorgan disease with the main clinical features being exocrine pancreatic insufficiency and diffuse bronchiectasis with chronic airway infection leading to respiratory failure and premature death. Over the past decades, major progress has been made by implementing multidisciplinary care, including nutritional support, airway clearance techniques and antibiotics in specialised CF centres. The past decade has further seen the progressive development of oral medications, called CFTR modulators, for which around 80% of people with CF are genetically eligible in Europe. CFTR modulators partially restore ion transport and lead to a rapid and major improvement in clinical manifestations and lung function, presumably resulting in longer survival. CFTR modulators have been game-changing in the care of people with CF. However, many questions remain unanswered, such as the long-term effects of CFTR modulators, especially when treatment is started very early in life, or the new CF-related disease emerging due to CFTR modulators. Moreover, severe complications of CF, such as diabetes or cirrhosis, are not reversed on CFTR modulators and around 20% of people with CF bear\n                    <jats:italic>CFTR<\/jats:italic>\n                    variants leading to a CFTR protein that is unresponsive to CFTR modulators. Challenges also arise in adapting CF care to a changing disease. In this review article, we highlight the new questions and challenges emerging from this revolution in CF care.\n                  <\/jats:p>","DOI":"10.1183\/16000617.0045-2024","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T09:40:28Z","timestamp":1727257228000},"page":"240045","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["New drugs, new challenges in cystic fibrosis care"],"prefix":"10.1183","volume":"33","author":[{"given":"Isabelle","family":"Fajac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4385-5888","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"2024102404224128000_33.173.240045.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2475911"},{"key":"2024102404224128000_33.173.240045.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.01.009"},{"key":"2024102404224128000_33.173.240045.3","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1999.79.1.S23"},{"key":"2024102404224128000_33.173.240045.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01307-2022"},{"key":"2024102404224128000_33.173.240045.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2216474"},{"key":"2024102404224128000_33.173.240045.6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.8","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219086"},{"key":"2024102404224128000_33.173.240045.9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chest.2022.07.004","article-title":"The changing epidemiology of cystic fibrosis: the implications for adult care","volume":"163","author":"Burgel","year":"2023","journal-title":"Chest"},{"key":"2024102404224128000_33.173.240045.10","doi-asserted-by":"crossref","first-page":"BSR20212006","DOI":"10.1042\/BSR20212006","article-title":"Molecular mechanisms of cystic fibrosis \u2013 how mutations lead to misfunction and guide therapy","volume":"42","author":"Farinha","year":"2022","journal-title":"Biosci Rep"},{"key":"2024102404224128000_33.173.240045.11","unstructured":"Zolin A , Orenti A , Jung A , et al. ECFSPR Annual Report 2021. Karup, European Cystic Fibrosis Society, 2023. www.ecfs.eu\/sites\/default\/files\/Annual%20Report_2021_09Jun2023_ECFSPR_final.pdf"},{"key":"2024102404224128000_33.173.240045.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"2024102404224128000_33.173.240045.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201301-0153OC"},{"key":"2024102404224128000_33.173.240045.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2024102404224128000_33.173.240045.15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0392OC"},{"key":"2024102404224128000_33.173.240045.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547"},{"key":"2024102404224128000_33.173.240045.17","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2397"},{"key":"2024102404224128000_33.173.240045.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202011-4153OC"},{"key":"2024102404224128000_33.173.240045.19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.21","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02029-2022"},{"key":"2024102404224128000_33.173.240045.22","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1164\/rccm.202109-2121LE","article-title":"Major decrease in lung transplantation for patients with cystic fibrosis in France","volume":"205","author":"Martin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404224128000_33.173.240045.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01402-2022"},{"key":"2024102404224128000_33.173.240045.24","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.25","first-page":"100829","article-title":"Patient perspectives following initiation of elexacaftor\u2013tezacaftor\u2013ivacaftor in people with cystic fibrosis and advanced lung disease","volume":"80","author":"Martin","year":"2021","journal-title":"Respir Med Res"},{"key":"2024102404224128000_33.173.240045.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2024102404224128000_33.173.240045.27","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2024.01.001","article-title":"Drug-induced liver injury associated with elexacaftor\/tezacaftor\/ivacaftor: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Shi","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MCP.0000000000001014","article-title":"Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort","volume":"29","author":"VanElzakker","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"2024102404224128000_33.173.240045.29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment and depression-related events","volume":"209","author":"Ramsey","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404224128000_33.173.240045.30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24\u2005months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102404224128000_33.173.240045.31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jcf.2021.01.007","article-title":"Challenges in the use of highly effective modulator treatment for cystic fibrosis","volume":"20","author":"Ramos","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.33","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccm.2022.06.005","article-title":"Novel applications of biomarkers and personalized medicine in cystic fibrosis","volume":"43","author":"Guimbellot","year":"2022","journal-title":"Clin Chest Med"},{"key":"2024102404224128000_33.173.240045.34","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S2213-2600(23)00324-7","article-title":"Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy","volume":"11","author":"Hisert","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024102404224128000_33.173.240045.35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ccm.2022.06.006","article-title":"Emerging approaches to monitor and modify care in the era of cystic fibrosis transmembrane conductance regulators","volume":"43","author":"Britto","year":"2022","journal-title":"Clin Chest Med"},{"key":"2024102404224128000_33.173.240045.36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcf.2021.05.004","article-title":"Effect of lumacaftor\u2013ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: results from the PROSPECT MCC sub-study","volume":"21","author":"Donaldson","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.37","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1164\/rccm.202112-2852LE","article-title":"Change in lung function after initiation of elexacaftor\u2013tezacaftor\u2013ivacaftor: do not forget anatomy!","volume":"205","author":"Martin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102404224128000_33.173.240045.38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01794-2023"},{"key":"2024102404224128000_33.173.240045.39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/MCP.0000000000000732","article-title":"Monitoring early stage lung disease in cystic fibrosis","volume":"26","author":"Nissenbaum","year":"2020","journal-title":"Curr Opin Pulm Med"},{"key":"2024102404224128000_33.173.240045.40","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/17476348.2021.1908131","article-title":"A multimodal approach to detect and monitor early lung disease in cystic fibrosis","volume":"15","author":"Mond\u00e9jar-L\u00f3pez","year":"2021","journal-title":"Expert Rev Respir Med"},{"key":"2024102404224128000_33.173.240045.41","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00247-022-05522-4","article-title":"Chest radiography and computed tomography imaging in cystic fibrosis: current challenges and new perspectives","volume":"53","author":"Ciet","year":"2023","journal-title":"Pediatr Radiol"},{"key":"2024102404224128000_33.173.240045.42","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"2024102404224128000_33.173.240045.43","doi-asserted-by":"crossref","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"2024102404224128000_33.173.240045.44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02153-2022"},{"key":"2024102404224128000_33.173.240045.45","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201407-310OC"},{"key":"2024102404224128000_33.173.240045.46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164232"},{"key":"2024102404224128000_33.173.240045.47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jcf.2021.08.031","article-title":"Comparison of microbial composition of cough swabs and sputum for pathogen detection in patients with cystic fibrosis","volume":"21","author":"Fenn","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.48","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jcf.2023.02.010","article-title":"Exhaled breath profiles to detect lung infection with Staphylococcus aureus in children with cystic fibrosis","volume":"22","author":"Licht","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135\u2005years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102404224128000_33.173.240045.50","first-page":"99","article-title":"Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor","volume":"35","author":"Nichols","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"2024102404224128000_33.173.240045.51","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.52","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jcf.2024.01.011","article-title":"Pancreatic enzyme prescription following ivacaftor licensing: a retrospective analysis of the US and UK cystic fibrosis registries","volume":"23","author":"Calthorpe","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.53","doi-asserted-by":"crossref","first-page":"17834","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Sci Rep"},{"key":"2024102404224128000_33.173.240045.54","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"2024102404224128000_33.173.240045.55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor\u2013tezacaftor\u2013ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.56","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","article-title":"Weight a minute: exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF","volume":"22","author":"Proud","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.57","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jcf.2023.05.010","article-title":"Nutritional considerations for a new era: a CF foundation position paper","volume":"22","author":"Leonard","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.58","doi-asserted-by":"crossref","first-page":"102899","DOI":"10.1016\/j.dsx.2023.102899","article-title":"Advances in cystic fibrosis-related diabetes: current status and future directions","volume":"17","author":"Lurquin","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"2024102404224128000_33.173.240045.59","first-page":"e41697","article-title":"The effects of elexacaftor, tezacaftor, and ivacaftor (ETI) on blood glucose in patients with cystic fibrosis: a systematic review","volume":"15","author":"Salazar-Barragan","year":"2023","journal-title":"Cureus"},{"key":"2024102404224128000_33.173.240045.60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jcf.2021.07.019","article-title":"Pregnancy in cystic fibrosis: review of the literature and expert recommendations","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.61","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ccm.2022.06.015","article-title":"Family planning and reproductive health in cystic fibrosis","volume":"43","author":"Meiss","year":"2022","journal-title":"Clin Chest Med"},{"key":"2024102404224128000_33.173.240045.62","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001289"},{"key":"2024102404224128000_33.173.240045.63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/coa.12310","article-title":"Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation","volume":"40","author":"Sheikh","year":"2015","journal-title":"Clin Otolaryngol"},{"key":"2024102404224128000_33.173.240045.64","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoto.2023.2701","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor therapy for chronic sinus disease in cystic fibrosis","volume":"149","author":"Sheikh","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2024102404224128000_33.173.240045.65","doi-asserted-by":"crossref","first-page":"104236","DOI":"10.1016\/j.amjoto.2024.104236","article-title":"Efficacy of elexacaftor\u2013tezacaftor\u2013ivacaftor on chronic rhinosinusitis in cystic fibrosis","volume":"45","author":"Di Gioia","year":"2024","journal-title":"Am J Otolaryngol"},{"key":"2024102404224128000_33.173.240045.66","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jcf.2016.09.003","article-title":"Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation","volume":"15","author":"Sermet-Gaudelus","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.67","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of Trikafta on bone density, body composition and exercise capacity in CF: a pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2024102404224128000_33.173.240045.68","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jcf.2019.08.017","article-title":"Cystic fibrosis bone disease treatment: current knowledge and future directions","volume":"18","author":"Putman","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2008.09.007"},{"key":"2024102404224128000_33.173.240045.70","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2024102404224128000_33.173.240045.71","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s44161-022-00030-y","article-title":"Identifying and preventing cardiovascular disease in patients with cystic fibrosis","volume":"1","author":"Saunders","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"2024102404224128000_33.173.240045.72","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00174-2023"},{"key":"2024102404224128000_33.173.240045.73","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01253-2023"},{"key":"2024102404224128000_33.173.240045.74","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs481"},{"key":"2024102404224128000_33.173.240045.75","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jcf.2021.07.004","article-title":"Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case\u2013control study","volume":"21","author":"Archangelidi","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.76","doi-asserted-by":"crossref","first-page":"1043691","DOI":"10.3389\/fpubh.2022.1043691","article-title":"Cancer incidence and prevalence in cystic fibrosis patients with and without a lung transplant in France","volume":"10","author":"Rousset-Jablonski","year":"2022","journal-title":"Front Public Health"},{"key":"2024102404224128000_33.173.240045.77","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102404224128000_33.173.240045.78","unstructured":"Vertex . Vertex announces European Medicines Agency validation for marketing authorization application extension for KAFTRIO\u00ae in combination with ivacaftor to include people with cystic fibrosis and responsive rare mutations. Date last updated: 24 November 2023. https:\/\/news.vrtx.com\/news-releases\/news-release-details\/vertex-announces-european-medicines-agency-validation-marketing"},{"key":"2024102404224128000_33.173.240045.79","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202101-0090LE"},{"key":"2024102404224128000_33.173.240045.80","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2022.10.011","article-title":"Treatment effects of elexacaftor\/tezacaftor\/ivacaftor in people with CF carrying non-F508del mutations","volume":"22","author":"Livnat","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2024102404224128000_33.173.240045.81","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01959-2023"},{"key":"2024102404224128000_33.173.240045.82","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02437-2022"},{"key":"2024102404224128000_33.173.240045.83","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01608-2"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0045-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:07:44Z","timestamp":1740355664000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0045-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":83,"journal-issue":{"issue":"173","published-online":{"date-parts":[[2024,9,25]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1183\/16000617.0045-2024"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0045-2024","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}